Clinical features and prognosis of high hyperdiploid childhood acute lymphoblastic leukemia: a multicenter retrospective analysis in Fujian Province, China
CAI Chun-Xia, ZHENG Yong-Zhi, LI Jian, WEN Hong, WENG Kai-Zhi, ZHUANG Shu-Quan, WU Xing-Guo, LE Shao-Hua
Department of Pediatric Hematology, Fujian Medical University Union Hospital, Fujian Institute of Hematology, Fujian Provincial Key Laboratory, Fuzhou 350001, China
Abstract Objective To study the clinical features and prognosis of high hyperdiploid (HHD) childhood acute lymphoblastic leukemia (ALL). Methods A retrospective analysis was performed on the medical data of 1 414 children who were newly diagnosed with ALL and were admitted to five hospitals in Fujian Province of China from April 2011 to December 2020. According to karyotype, they were divided into two groups: HHD (n=172) and non-HHD (n=1 242). The clinical features and treatment outcome were compared between the two groups, and the factors influencing the prognosis were further explored. Results Among the 1 414 children with ALL, 172 (12.16%) had HHD. Compared with the non-HHD group, the HHD group had significantly lower proportions of children with risk factors for poor prognosis at diagnosis (age of onset ≥10 years or <1 year, white blood cell count ≥50×109/L, and T-cell phenotype) or positive fusion genes (TEL-AML1, BCR-ABL1, E2A-PBX1, and MLL gene rearrangement) (P<0.05). The HHD group had a significantly higher proportion of children with minimal residual disease (MRD) <0.01% at the end of induction chemotherapy (P<0.05). The 10-year event-free survival (EFS) rate and overall survival (OS) rate in the HHD group were significantly higher than those in the non-HHD group (P<0.05). The univariate analysis showed that the number of chromosomes of 58-66, trisomy of chromosome 10, trisomy of chromosome 17, bone marrow MRD <1% on day 15 or 19 of induction chemotherapy, and bone marrow MRD <0.01% on day 33 or 46 of induction chemotherapy were associated with a higher EFS rate (P<0.05), and trisomy of chromosome 10 was associated with a higher OS rate (P<0.05). The multivariate Cox analysis showed that trisomy of chromosome 17 was closely associated with a high EFS rate (P<0.05). Conclusions The ALL children with HHD have few risk factors for poor prognosis at diagnosis and often have good prognosis. The number of chromosomes and trisomy of specific chromosomes are associated with prognosis in these children.
CAI Chun-Xia,ZHENG Yong-Zhi,LI Jian et al. Clinical features and prognosis of high hyperdiploid childhood acute lymphoblastic leukemia: a multicenter retrospective analysis in Fujian Province, China[J]. CJCP, 2023, 25(1): 38-45.
CAI Chun-Xia,ZHENG Yong-Zhi,LI Jian et al. Clinical features and prognosis of high hyperdiploid childhood acute lymphoblastic leukemia: a multicenter retrospective analysis in Fujian Province, China[J]. CJCP, 2023, 25(1): 38-45.
Dastugue N, Suciu S, Plat G, et al. Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results[J]. Blood, 2013, 121(13): 2415-2423. PMID: 23321258. DOI: 10.1182/blood-2012-06-437681.
Kato M, Imamura T, Manabe A, et al. Prognostic impact of gained chromosomes in high-hyperdiploid childhood acute lymphoblastic leukaemia: a collaborative retrospective study of the Tokyo Children's Cancer Study Group and Japan Association of Childhood Leukaemia Study[J]. Br J Haematol, 2014, 166(2): 295-298. PMID: 24628674. DOI: 10.1111/bjh.12836.
Cui L, Li ZG, Chai YH, et al. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: the first nation-wide prospective multicenter study in China[J]. Am J Hematol, 2018, 93(7): 913-920. PMID: 29675840. DOI: 10.1002/ajh.25124.
Brothman AR, Persons DL, Shaffer LG. Nomenclature evolution: changes in the ISCN from the 2005 to the 2009 edition[J]. Cytogenet Genome Res, 2009, 127(1): 1-4. PMID: 20110655. DOI: 10.1159/000279442.
Paulsson K, Forestier E, Andersen MK, et al. High modal number and triple trisomies are highly correlated favorable factors in childhood B-cell precursor high hyperdiploid acute lymphoblastic leukemia treated according to the NOPHO ALL 1992/2000 protocols[J]. Haematologica, 2013, 98(9): 1424-1432. PMID: 23645689. PMCID: PMC3762100. DOI: 10.3324/haematol.2013.085852.
Moorman AV, Richards SM, Martineau M, et al. Outcome heterogeneity in childhood high-hyperdiploid acute lymphoblastic leukemia[J]. Blood, 2003, 102(8): 2756-2762. PMID: 12829593. DOI: 10.1182/blood-2003-04-1128.
Szczepański T, Harrison CJ, van Dongen JJ. Genetic aberrations in paediatric acute leukaemias and implications for management of patients[J]. Lancet Oncol, 2010, 11(9): 880-889. PMID: 20435517. DOI: 10.1016/S1470-2045(09)70369-9.
Heerema NA, Sather HN, Sensel MG, et al. Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (>50 chromosomes)[J]. J Clin Oncol, 2000, 18(9): 1876-1887. PMID: 10784628. DOI: 10.1200/JCO.2000.18.9.1876.
Moorman AV, Ensor HM, Richards SM, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial[J]. Lancet Oncol, 2010, 11(5): 429-438. PMID: 20409752. DOI: 10.1016/S1470-2045(10)70066-8.
Li X, Li J, Hu Y, et al. A comprehensive cytogenetic classification of 1466 Chinese patients with de novo acute lymphoblastic leukemia[J]. Leuk Res, 2012, 36(6): 720-726. PMID: 22264634. DOI: 10.1016/j.leukres.2011.12.016.
Chen B, Wang YY, Shen Y, et al. Newly diagnosed acute lymphoblastic leukemia in China (I): abnormal genetic patterns in 1 346 childhood and adult cases and their comparison with the reports from western countries[J]. Leukemia, 2012, 26(7): 1608-1616. PMID: 22382891. DOI: 10.1038/leu.2012.26.
Liang DC, Shih LY, Yang CP, et al. Frequencies of ETV6-RUNX1 fusion and hyperdiploidy in pediatric acute lymphoblastic leukemia are lower in far east than west[J]. Pediatr Blood Cancer, 2010, 55(3): 430-433. PMID: 20658612. DOI: 10.1002/pbc.22628.
Sutcliffe MJ, Shuster JJ, Sather HN, et al. High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI standard-risk B-precursor acute lymphoblastic leukemia: a Children's Oncology Group (COG) initiative[J]. Leukemia, 2005, 19(5): 734-740. PMID: 15789069. DOI: 10.1038/sj.leu.2403673.
Enshaei A, Vora A, Harrison CJ, et al. Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials[J]. Lancet Haematol, 2021, 8(11): e828-e839. PMID: 34715050. PMCID: PMC8567211. DOI: 10.1016/S2352-3026(21)00304-5.
Vora A, Goulden N, Wade R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial[J]. Lancet Oncol, 2013, 14(3): 199-209. PMID: 23395119. DOI: 10.1016/S1470-2045(12)70600-9.
